Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01010126
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:01.678194+00:00
Published At
2019-01-25T00:00:00+00:00
Record Updated At
2019-01-25
Results Posted At
2019-01-25
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Hepatocellular Carcinoma", "Advanced Adult Hepatocellular Carcinoma", "Endometrial Serous Adenocarcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Lung Carcinoid Tumor", "Malignant Pancreatic Gastrinoma", "Malignant Pancreatic Glucagonoma", "Malignant Pancreatic Insulinoma", "Malignant Pancreatic Somatostatinoma", "Metastatic Digestive System Neuroendocrine Tumor G1", "Ovarian Carcinosarcoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Pancreatic Alpha Cell Adenoma", "Pancreatic Beta Cell Adenoma", "Pancreatic Delta Cell Adenoma", "Pancreatic G-Cell Adenoma", "Pancreatic Polypeptide Tumor", "Recurrent Adult Liver Carcinoma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IIIC Uterine Corpus Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer", "Uterine Carcinosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-01-25"
protocolSection.identificationModule.nctId
"NCT01010126"
protocolSection.identificationModule.officialTitle
"A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2019-01-25"

Study condition terms

  • Adult Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Adult Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Localized Non-Resectable Adult Liver Carcinoma (protocolSection.conditionsModule.conditions)
  • Lung Carcinoid Tumor (protocolSection.conditionsModule.conditions)
  • Malignant Pancreatic Gastrinoma (protocolSection.conditionsModule.conditions)
  • Malignant Pancreatic Glucagonoma (protocolSection.conditionsModule.conditions)
  • Malignant Pancreatic Insulinoma (protocolSection.conditionsModule.conditions)
  • Malignant Pancreatic Somatostatinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Digestive System Neuroendocrine Tumor G1 (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Seromucinous Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Surface Papillary Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Alpha Cell Adenoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Beta Cell Adenoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Delta Cell Adenoma (protocolSection.conditionsModule.conditions)
  • Pancreatic G-Cell Adenoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Polypeptide Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Liver Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Digestive System Neuroendocrine Tumor G1 (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Pancreatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Uterine Corpus Carcinoma (protocolSection.conditionsModule.conditions)
  • Regional Digestive System Neuroendocrine Tumor G1 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IVA Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IVB Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Uterine Carcinosarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.